Carbon dioxide (CO2) is a naturally occurring gas that readily diffuses across body tissues
and membranes. Data from earlier clinical studies conducted in 975 subjects with allergic
rhinitis have shown that nasally administered CO2 may provide relief of the associated
symptoms. Symptom relief has been shown to occur as soon as 10 minutes after administration,
and may persist for four to six hours.
This study aims to assess the consumer appeal of a prototype CO2 delivery device, as well as
evaluate its perceived effectiveness for nasal congestion. Properly consented subjects who
qualify and choose to participate in the clinical study will be administered nasal CO2 under
medical supervision, wait a period of 1 hour in clinic, and then be dispensed a device for
self-treatment at home. Subjects will return to the clinic on day 7 for final evaluation and
completion of assessment questionnaires.